Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)
Completed
- Conditions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1919
- Registration Number
- NCT01181778
A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 80
- Registration Number
- NCT01165424
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1547
- Registration Number
- NCT01154036
Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 307
- Registration Number
- NCT01146418
Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1424
- Registration Number
- NCT01144416
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT01142596
Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Completed
- Conditions
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 343
- Registration Number
- NCT01140048
Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 333
- Registration Number
- NCT01135134
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 8
- Registration Number
- NCT01101464
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 532
- Registration Number
- NCT01098110
© Copyright 2024. All Rights Reserved by MedPath